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Background: Vaccination against human papillomavirus (HPV), predominantly targeting young females, has been
introduced in many countries. Decisions to implement programs, which have involved substantial investment by
governments, have in part been based on findings from cost-effectiveness models. Now that vaccination programs
have been in place for some years, it is becoming possible to observe their effects, and compare these with model
effectiveness predictions made previously.
Findings: Australia introduced a publicly-funded HPV vaccination program in 2007. Recently reported Australian
data from a repeat cross-sectional survey showed a substantial (77%) fall in HPV16 prevalence in women aged
18–24 years in 2010–2011, compared to pre-vaccination levels. We have previously published model predictions for
the population-wide reduction in incident HPV16 infections post-vaccination in Australia. We compared prior
predictions from the same model (including the same assumed uptake rates) for the reduction in HPV16 prevalence
in women aged 18–24 years by the end of 2010 with the observed data. Based on modelled vaccine uptake which
is consistent with recent data on three-dose uptake (78% at 12–13 years; lower uptake in older catch-up age
cohorts), we had predicted a 70% reduction in prevalence in 18–24 year old females by the end of 2010. Based on
modelled vaccine uptake consistent with recent national data for two-dose coverage and similar to that reported
by women in the cross-sectional study, we had predicted a 79% reduction.
Conclusions: A close correspondence was observed between the prior model predictions and the recently
reported findings on the rapid drop in HPV prevalence in Australia. Because broadly similar effectiveness predictions
have been reported from other models used for cost-effectiveness predictions, this provides reassurance that the
substantial public investment in HPV vaccination has been grounded in valid estimates of the effects of vaccination.
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Background
Vaccination against human papillomavirus (HPV), pre-
dominantly targeting young females, has been intro-
duced in many countries. Implementation of publicly-
funded programs has involved substantial investment by
governments. In Australia, for example, the government
budgeted approximately A$580 million over the first five
years of its National HPV Vaccination Program for
females (2007–2011) [1,2]. In most affluent countries,* Correspondence: megan.smith@unsw.edu.au
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distribution, and reproduction in any mediumdecisions to implement HPV vaccination on a widespread
basis have in part been made on the basis of findings from
cost-effectiveness models [3]. The cost-effectiveness of
HPV vaccination is critically dependent on its effective-
ness in preventing HPV infection, the associated projected
fall in population incidence and prevalence of infection,
and thus prevention of the downstream sequelae [3].
These sequelae include the development of cervical pre-
cancerous abnormalities, their diagnosis and treatment,
and the development of invasive cervical cancer, as well
the development of anogenital warts and other types of
HPV-associated cancer in the anogenital tract and head
and neck in both females and males [4].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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some years, it is becoming possible to observe their effects
on health outcomes (both in the target population and
also, due to herd immunity, in other populations), outside
of the context of clinical trials. Australia implemented a
National HPV Vaccination Program in 2007, with routine
vaccination of 12–13 year old females and catch-up in
females aged 13–26 years to 2009 with the quadrivalent
vaccine (Gardasil®, Merck&Co., Whitehouse Station, NJ
USA). The National HPV Vaccination Program is primar-
ily delivered through schools, although missed doses can
be obtained from primary care. The catch-up program
was delivered through schools for school-aged girls, and
through primary care for older (18–26 years) females or
females who were no longer at school. Commencing from
2013, the National HPV Vaccination Program was ex-
tended to include routine vaccination of 12–13 year old
males and a two year catch-up program for boys aged
14–15 years during 2013 and 2014. Australia offers
unique opportunities to observe the early impacts of
HPV vaccination, as its program commenced earlier
and its catch-up component was more extensive than
in most other countries. Post-vaccination reductions
have already been documented in Australia in genital
warts [5,6], high-grade cervical abnormalities [7,8], and
most recently, HPV prevalence [9], in young women.
Tabrizi et al. recently reported a substantial fall in HPV
prevalence in a repeat cross-sectional study in Australian
women aged 18–24 years recruited during 2010–2011,
compared to women of the same age recruited in 2005–
2007, which was prior to the commencement of the
vaccination program [9]. HPV16 prevalence was found
to be 77% lower in the post-vaccine group than in the
pre-vaccine group, and the authors found a significant
reduction in the prevalence of vaccine-included HPV
types (HPV16,18,6,11) after adjusting for other risk factors
(adjusted OR = 0.16; 95%CI: 0.09-0.26) [9]. Self-reported
vaccine uptake was high in the post-vaccination study
sample, who were aged approximately 14–21 years in
2007 (86.4% one dose; 70.6% three doses), compared to
the population uptake estimated for that age group based
on data held by the National HPV Vaccination Program
Register (NHPVR) (estimated 72.4% one dose; 52.2% three
doses) [9-11]. The actual difference in uptake may be
smaller than these figures suggest, however, as related
work in Australia has suggested self-reported vaccination
status tends to slightly over-estimate uptake, and con-
versely, national coverage data from the NHPVR may be
under-reported [9,11]. Under-reporting, particularly of
doses delivered through primary care to females no longer
in school or females who missed doses at school, is
thought to be likely as notification of these doses to the
NHVPR was voluntary (although a small incentive pay-
ment of A$ 6 per dose notified was available). Also,because of the very rapid roll-out of the vaccination pro-
gram, the NHVPR did not commence operations until
June 2008, the year after the program commenced, and
providers needed to retain data for doses administered
prior to this time [11]. Under-reporting to the NHVPR is
also suggested by data from earlier surveys, by discrepan-
cies between data for doses distributed versus doses noti-
fied, and by wide variations in reported uptake between
states, with higher uptake reported in states having centra-
lised reporting mechanisms in place even though the vac-
cination program was promoted at a national level [11].
We have previously published model predictions for the
reduction in incident HPV16 infections post-vaccination
in Australia, across the female population [12,13]. The
aim of this study was to compare these previous model
predictions with the findings of Tabrizi et al., which re-
quired specific examination of the prior model predictions
for HPV prevalence in the specific age group and at the
specific timepoint reported by Tabrizi et al. [9]. We also
compared the original estimates of vaccine uptake used in
the previous analysis with observed uptake in Australia,
and in relation to the women in Tabrizi et al. [9,12].
Methods
In line with methods used by several other groups [3], we
used a dynamic model of HPV transmission and vaccin-
ation. This is the most comprehensive method of estimat-
ing the effectiveness, and hence the most comprehensive
method of estimating the cost-effectiveness, of HPV vac-
cination, and takes into account herd immunity, the po-
tential for prior HPV exposure in catch-up cohorts, and
detailed and differing coverage among the catch-up co-
horts [3]. This model has been described in detail previ-
ously [12-14]. Briefly, the model simulates the potential
transmission of HPV16 during heterosexual partnerships
in a population which is closed and stratified by sex, age
and level of sexual activity. Model parameters were ob-
tained via literature reviews and fitting to observed data
[12,13]. Prior to modelling the effect of vaccination, the
model was calibrated to cross-sectional age-specific survey
data on HPV prevalence in sexually active women, from
an initial pre-vaccination cross-sectional survey in women
presenting for cervical screening in Australia (WHINURS)
[12,14,15]. The pre-vaccine sample in Tabrizi et al. also
comprised the subset of women from WHINURS who
were 18–24 years of age at the time of recruitment.
To compare model predictions with the findings of
Tabrizi et al. [9], we extracted the model-predicted
prevalence at the end of 2010 (around the midpoint of
the recruitment period for Tabrizi et al. [9]) among
women aged 18–24 years during the period 2010–2011
(the “comparison population”). Women in the model
who were aged 24 in 2010 or aged 18 in 2011 were given
a lower (50%) weighting in the model-based prevalence
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both 2010 and 2011, since these women were not eligible
for recruitment over the entire period of the study. This
group of women were offered vaccination in Australia
during 2007–2009 as 14–21 year olds.
We had modelled uptake in terms of effective vaccin-
ation; initially we had assumed three vaccine doses would
be needed to achieve the efficacy levels observed in clin-
ical trials [12]. However, recent data suggest the possibility
that two-dose efficacy may be comparable to three-dose
efficacy [16,17]; thus, modelled predictions based on
coverage which is comparable to two-dose coverage rates
achieved may also be relevant.
Vaccine uptake scenarios (and all other model parameters)
were unchanged compared to our previous analysis [12].
The early estimates of uptake which were incorporated in
the original modelled analysis have now been compared to
recently reported data on achieved uptake in Australia
[10,11,18] and to that reported by the specific group of
women reported on by Tabrizi et al. [9]. Table 1 shows
how uptake in the comparison population (females
aged 18–24 years in 2010–2011) in each of the scenar-
ios modelled compares to achieved uptake, both in the
Australian female population that age, and in the spe-
cific group of women reported on by Tabrizi et al. [9].
Full details of the age-specific uptake rates we had as-
sumed are reproduced in Additional file 1: Table S1
[12]. In the main modelled scenario, effective vaccine
uptake in the comparison population of females was
57.7% (feasible range: 48.8-68.6%). This modelled up-
take is broadly consistent with recent data on three-
dose uptake in Australia in females aged 18–24 years in
2010–2011 (57.7% modelled vs 52.2% estimated from
reported data [9-11,19]), but lower than that reported
by women in Tabrizi et al. (70.6%; although this was
potentially over-reported) [9]. Uptake in the main sce-
nario we modelled is also broadly consistent with re-
cent estimates of three-dose uptake in younger females
(aged less than 18 years in 2007), but higher than re-
ported three-dose uptake in females vaccinated in the
primary-care-based catch-up program (aged 18 or olderTable 1 Uptake in the comparison populationa: comparison o
Australian population, and modelled population
Vaccine uptake Repeat cross-sectional sample in Tabrizi et
(females 18–24 years)a
> = 1 dose 85.6%c
> = 2 doses [not reported]
3 doses 70.6%c
Effectively vaccinatedd
aFemales aged 18–24 years in 2010–2011b calculated from published data from NH
as doses are not explicitly modelled; uptake in the model reflects the proportion w
observed in clinical trialse Main scenario used in original analysis, based on early es
estimates of coverage.in 2007) (Additional file 1: Table S1), although potential
under-reporting to the NHPVR should be taken into
account [9,11]. In sensitivity analysis we had also mod-
elled a wide range of possible uptake scenarios [12].
The higher end of the feasible range we had examined
(68.6% in the comparison population) is consistent with re-
cent data for two-dose coverage in Australia in females
aged 18–24 years in 2010–2011 when potential under-
reporting to the NHPVR is taken into account (estimated
63.6-67.7%) [9,11] and also similar to that reported by
women in Tabrizi et al. (70.6%) [9] (Table 1). The higher
end of the feasible range we had modelled is also broadly
consistent with reported national two dose uptake in youn-
ger females (aged less than 18 years in 2007), but is higher
than reported two-dose uptake in females vaccinated in
the primary-care-based catch-up program (aged 18 or
older in 2007) (Additional file 1: Table S1), although it is
possible that this two-dose data was also under-reported to
the NHVPR [11,20]. The lower end of the feasible range
we had modelled can now be seen as lower than reported
three-dose uptake (48.8% modelled vs 52.2% estimated
from reported data [9-11,19]), particularly when potential
under-reporting to the NHPVR is taken into account, and
substantially lower than that reported by women in Tabrizi
et al. (Table 1, Additional file 1: Table S1) [9].
Results
In the main scenario examined (modelled uptake in the
comparison population 57.7%; broadly comparable to ob-
served three-dose uptake in Australian females that age
(52.2-55.1%), but lower than self-reported uptake in
Tabrizi et al. (70.6%) [9]), we had predicted a 41% reduc-
tion in incident HPV16 infections in females across all
ages by the beginning of 2010 [12]. When we examined
predictions specifically for females aged 18–24 years from
the same uptake scenario, we found a 60% reduction in in-
cident infections in 18–24 year old females by the begin-
ning of 2010. This in turn corresponded to a 63%
reduction in HPV16 prevalence in females in this age
group. Considering model predictions specifically for a
time point and group of females broadly equivalent tof uptake in females included in Tabrizi et al. [9],
al. [9] Australian population Modelled population




57.7%e (48.8 - 68.6%)f
VPR; potentially under-reported [10,11]c self-reported uptaked Not applicable,
ho are effectively vaccinated ie doses needed to achieve the efficacy levels
timates of coveragef Feasible range used in original analysis, based on early
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old at some point during the recruitment period (2010–
2011)), the model predicted a reduction in HPV16 preva-
lence of 70% by the end of 2010 (close to the midpoint of
recruitment in Tabrizi et al.) [9]. Based on the higher end of
the modelled feasible range (assumed uptake in the com-
parison population 68.6%; broadly consistent with two-dose
data for that group (63.6-67.7%) [20]; similar to three-dose
uptake reported by women in Tabrizi et al. (70.6%) [9]), we
predicted a 79% reduction in 18–24 year olds by the end of
2010. Based on the lower end of the feasible range (assumed
uptake in the comparison population 48.8%; lower than
three-dose uptake based on NHVPR data (52.2-55.1%);
considerably lower than the self-reported three-dose
uptake rates in Tabrizi et al. (70.6%) [9]), we predicted
a 64% reduction in prevalence in 18–24 year old fe-
males by the end of 2010.
Discussion
This predicted 64%-79% fall in HPV16 infections in 18–
24 year old females by the end of 2010 accords well with
the data from Tabrizi et al., who reported a 77% reduction
in HPV16 prevalence, [9] especially in light of the higher
self-reported uptake in the study group, and also the fact
that the upper end of our originally modelled feasible range
for uptake may better reflect observed uptake in the popu-
lation, under-reporting to the NHVPR, and the potential
for high two-dose efficacy.
While our model incorporated the best estimates of up-
take available at the time, and attempted to encompass a
broad feasible range, there are now more data available on
both uptake achieved by the program and the efficacy of
two versus three doses of quadrivalent vaccine. The up-
take we assumed for our original predictions [12] is gener-
ally consistent with reported three-dose uptake after
accounting for under-reporting to the NHVPR in the
older catch-up cohorts [10,11,20]. The upper end of the
feasible range examined is broadly consistent with ob-
served two-dose data, in the context of under-reporting to
the NHVPR. However, based on the latest data on uptake,
it now seems that the lowest end of the feasible uptake
range we had assumed (48.8% for the comparison popula-
tion; 70% at age 12, and ranging from 70% at age 13 to
15% at age 26 years) is below observed three-dose uptake,
and so our original predictions based on this end of the
range may be less relevant, especially in the context of
under-reporting to the NHVPR and two-dose efficacy be-
ing high [16,17]. As a result of these observations, our pre-
dicted reductions in HPV16 prevalence in the range of 70-
79% now seem the most relevant for the national Austra-
lian population, although even they may not fully account
for under-reporting to the NHVPR in the context of high
two-dose efficacy. They may also underestimate the effects
seen in a group like those included in Tabrizi et al., wherethree-dose uptake was potentially somewhat higher than
average for other females of the same age [9]. Two-dose
uptake was not reported for this group, but since it was al-
most certainly higher than three-dose uptake, it was thus
higher than in any scenario we modelled. Consistent with
this, the reduction in the prevalence of vaccine-included
types observed by Tabrizi et al. was substantial, after
adjusting for differences in age and hormonal contracep-
tive use in the pre- and post-vaccination study samples [9].
Models of HPV vaccination typically assume high vaccine
efficacy in the base case [3], based on the “per-protocol” re-
sults from clinical trials which reflect efficacy in HPV-naïve
individuals. In order to make predictions about program ef-
fectiveness, and thus cost-effectiveness, models use this in-
formation in conjunction with other epidemiological and
behavioural data, in order to take into account the inter-
action of other complex factors such as the natural history
of HPV infection, and sexual behaviour and contact pat-
terns. The outcomes of real world programs which are ob-
servable in the short term, predominantly reflecting
outcomes in older catch- cohorts, will be particularly influ-
enced by prior exposure to HPV and thus the complex
interaction of these factors. Taking these interactions into
account is necessary to translate efficacy data from clinical
trials into predictions of effectiveness in the real world, but
can make models complex and less transparent to policy-
makers and clinicians. This makes it especially important to
check prior model predictions when the data become avail-
able to do so; however this is not routinely done. Our model
findings for a rapid drop in HPV incidence and prevalence
in young women and predictions of substantial reductions
over the longer term have been broadly mirrored by findings
from other groups using dynamic models where the impact
on HPV infections have been reported [21-23]. Findings
from these and other models have been influential in cost-
effectiveness decisions in affluent countries [3].
The joint task force of the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR)
and the Society for Medical Decision Making recom-
mended as best practice for medical decision-making
models that model predictions of future events should
be tested against observed data, when these data subse-
quently become available [24]. This is important, in
order to test the reliability of model-based predictions,
and justify the substantial public investment made on
the basis of those predictions. To our knowledge, this is
the first study which has compared prior model predic-
tions of HPV vaccination program impacts to subse-
quently observed program outcomes, even though policy
decisions around HPV vaccination have generally been
made on the basis of such models. Australia is among
the first countries in the world where this has been pos-
sible, as Tabrizi et al. noted that, as far as they were
aware, their findings “were the first genoprevalence-
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ation outside the setting of a clinical trial”[9].
Conclusions
The investments in HPV vaccination programs around
the world have been substantial. Such investments in af-
fluent countries have been made, in part, on the basis of
predictions from cost-effectiveness models. However, prior
model predictions for vaccine effectiveness in a ‘real
world’ population have not previously been compared to
observed data after the vaccination program has been
implemented.
The close correspondence between these prior model
predictions and the recently reported findings on the rapid
drop in HPV prevalence rates in Australia [9] provides
reassurance that the substantial public investment in HPV
vaccination has been grounded in valid estimates of the
effects of vaccination programs.
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